CN110392572A - 治疗克罗恩病和溃疡性结肠炎的方法 - Google Patents

治疗克罗恩病和溃疡性结肠炎的方法 Download PDF

Info

Publication number
CN110392572A
CN110392572A CN201880016862.XA CN201880016862A CN110392572A CN 110392572 A CN110392572 A CN 110392572A CN 201880016862 A CN201880016862 A CN 201880016862A CN 110392572 A CN110392572 A CN 110392572A
Authority
CN
China
Prior art keywords
patient
weeks
acceptable salt
pharmaceutically acceptable
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880016862.XA
Other languages
English (en)
Chinese (zh)
Inventor
R.B.萨卡
S.容格维尔特
A.P.马哈多德拉塞尔达
A.M.罗宾逊
J.J.V.埃内霍萨
A.L.潘根
M-E.穆罕默德
A.奥特曼
B.克吕恩德
A.D.阿利安
T.B.波尔查德特
F.L.诺尔斯特隆
A.Y.谢赫
M.M.马尔赫恩
J.加延特
P.J.马罗姆
P.T.迈尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61750557&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN110392572(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AbbVie Inc filed Critical AbbVie Inc
Priority to CN202510812764.9A priority Critical patent/CN120661512A/zh
Publication of CN110392572A publication Critical patent/CN110392572A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201880016862.XA 2017-03-09 2018-03-09 治疗克罗恩病和溃疡性结肠炎的方法 Pending CN110392572A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510812764.9A CN120661512A (zh) 2017-03-09 2018-03-09 治疗克罗恩病和溃疡性结肠炎的方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762469337P 2017-03-09 2017-03-09
US62/469337 2017-03-09
US201762470565P 2017-03-13 2017-03-13
US62/470565 2017-03-13
US201762483289P 2017-04-07 2017-04-07
US62/483289 2017-04-07
US201762593629P 2017-12-01 2017-12-01
US62/593629 2017-12-01
PCT/US2018/021800 WO2018165581A1 (en) 2017-03-09 2018-03-09 Methods of treating crohn's disease and ulcerative colitis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510812764.9A Division CN120661512A (zh) 2017-03-09 2018-03-09 治疗克罗恩病和溃疡性结肠炎的方法

Publications (1)

Publication Number Publication Date
CN110392572A true CN110392572A (zh) 2019-10-29

Family

ID=61750557

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880016862.XA Pending CN110392572A (zh) 2017-03-09 2018-03-09 治疗克罗恩病和溃疡性结肠炎的方法
CN202510812764.9A Pending CN120661512A (zh) 2017-03-09 2018-03-09 治疗克罗恩病和溃疡性结肠炎的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510812764.9A Pending CN120661512A (zh) 2017-03-09 2018-03-09 治疗克罗恩病和溃疡性结肠炎的方法

Country Status (9)

Country Link
US (3) US20190046527A1 (https=)
EP (2) EP3592353A1 (https=)
JP (3) JP2020510016A (https=)
CN (2) CN110392572A (https=)
AU (2) AU2018230500B2 (https=)
BR (1) BR112019018576A2 (https=)
MX (2) MX2019010733A (https=)
TW (2) TWI851536B (https=)
WO (2) WO2018165581A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114380837A (zh) * 2021-12-27 2022-04-22 上海邈金医药科技有限公司 一种具有Janus激酶抑制活性的化合物、包括该化合物的组合物及其应用
CN120699157A (zh) * 2025-07-16 2025-09-26 安康市中心医院 一种治疗溃疡性结肠炎的恢复肠屏障功能抗体及其应用

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US20210228575A1 (en) 2019-09-30 2021-07-29 Abbvie Inc. Treating spondyloarthritic and psoriatic conditions with upadacitinib
US11512092B2 (en) * 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913990RA (en) 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
AU2018230500B2 (en) * 2017-03-09 2024-03-07 Abbvie Inc. Methods of treating Crohn's disease and ulcerative colitis
US11564922B2 (en) 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
CN112770756A (zh) * 2018-09-29 2021-05-07 苏州科睿思制药有限公司 一种Upadacitinib的晶型及其制备方法和用途
WO2020115212A1 (en) * 2018-12-05 2020-06-11 Lek Pharmaceuticals D.D. Crystalline phosphate salt of selective jak1 inhibitor upadacitinib
CN111909160B (zh) * 2019-05-09 2024-05-28 苏州鹏旭医药科技有限公司 一种乌帕替尼盐类化合物及其制备方法
CN110101669A (zh) * 2019-06-11 2019-08-09 南京新酶合医药科技有限公司 一种乌帕替尼颗粒的生产工艺
KR20230038229A (ko) 2020-07-08 2023-03-17 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. 우파다시티닙의 결정형, 이의 제조 방법 및 이의 용도
EP4271380A4 (en) * 2020-12-29 2025-01-22 Abbvie Inc. UPADACITINIB EXTENDED RELEASE FORMULATIONS
KR20240148324A (ko) * 2022-01-13 2024-10-11 애브비 인코포레이티드 유해 약물 상호작용 및 효과를 피하기 위한 우파다시티닙의 투여 방법
CA3248817A1 (en) * 2022-01-20 2023-07-27 Renata Pharmaceutical (Ireland) Limited Extended-release pharmaceutical composition of Upadacitinib
EP4583877A1 (en) * 2022-09-09 2025-07-16 Intas Pharmaceuticals Ltd. Upadacitinib formulation
US12531141B2 (en) * 2023-01-17 2026-01-20 Children's Hospital Medical Center Model-informed precision dosing systems for treatment of inflammatory bowel disease
WO2025149974A1 (en) * 2024-01-11 2025-07-17 Takeda Pharmaceutical Company Limited Combination therapy with an anti-alpha4beta7 antibody

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015061665A1 (en) * 2013-10-24 2015-04-30 Abbvie Inc. Jak1 selective inhibitor and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448253B1 (en) 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
GB0115393D0 (en) 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
GB0124299D0 (en) 2001-10-10 2001-11-28 Astrazeneca Ab Crystal structure of enzyme and uses thereof
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
WO2005110410A2 (en) 2004-05-14 2005-11-24 Abbott Laboratories Kinase inhibitors as therapeutic agents
CN100381175C (zh) 2004-10-09 2008-04-16 山西中医学院 一种微乳制剂及其制备方法
ES2545907T3 (es) 2005-12-29 2015-09-16 Abbvie Inc. Inhibidores de proteína quinasa
EP2068869A4 (en) 2006-10-06 2011-05-25 Abbott Lab NEW IMIDAZOTHIAZOLE AND IMIDAZOXAZOLE
DK2152250T3 (da) 2007-05-07 2019-12-09 Evonik Degussa Gmbh Faste doseringsformer, der omfatter et enterisk overtræk, med accelereret lægemiddelfrigivelse
WO2009005675A1 (en) 2007-06-28 2009-01-08 Abbott Laboratories Novel triazolopyridazines
EP2271317B1 (de) 2008-03-28 2017-04-19 Boehringer Ingelheim International GmbH Verfahren zur herstellung von säurepellets
CN104592231A (zh) 2008-06-10 2015-05-06 Abbvie公司 新的三环化合物
CN101904814A (zh) 2009-06-04 2010-12-08 上海恒瑞医药有限公司 制备载药乳剂的方法
US9078830B2 (en) 2009-07-31 2015-07-14 Ranbaxy Laboratories Limited Multi-layered, multiple unit pharmaceutical compositions
RU2711869C3 (ru) 2009-12-01 2022-02-02 Эббви Инк. Имидазопирролопиразиновые производные, полезные для лечения заболеваний, вызванных аномальной активностью протеинкиназ Jak1, Jak3 или Syk
FR2991171B1 (fr) 2012-06-01 2014-05-23 Galderma Res & Dev Procede de preparation d'une composition dermatologique comprenant des oleosomes
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
SG11201701292XA (en) 2014-08-27 2017-03-30 Abbvie Inc Topical formulation
ES3063790T3 (en) 2015-06-09 2026-04-20 Lonza Sales Ag Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913990RA (en) 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
JP2020502126A (ja) * 2016-12-14 2020-01-23 プロジェニティ， インコーポレイテッド 消化管疾病のｊａｋ阻害薬による治療
AU2018230500B2 (en) * 2017-03-09 2024-03-07 Abbvie Inc. Methods of treating Crohn's disease and ulcerative colitis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015061665A1 (en) * 2013-10-24 2015-04-30 Abbvie Inc. Jak1 selective inhibitor and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MOHAMED-ESLAM F. MOHAMED等: ""Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis"", 《CLIN PHARMACOKINET》 *
U.S. NATIONAL LIBRARY OF MEDICINE: ""A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn"s Disease Who Have Inadequately Responded to or Are ..."", 《HTTPS://CLINICALTRIALS.GOV/CT2/HISTORY/NCT02365649?V_11=VIEW#STUDYPAGETOP》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114380837A (zh) * 2021-12-27 2022-04-22 上海邈金医药科技有限公司 一种具有Janus激酶抑制活性的化合物、包括该化合物的组合物及其应用
CN120699157A (zh) * 2025-07-16 2025-09-26 安康市中心医院 一种治疗溃疡性结肠炎的恢复肠屏障功能抗体及其应用

Also Published As

Publication number Publication date
EP3592353A1 (en) 2020-01-15
US20210361647A1 (en) 2021-11-25
JP2024009963A (ja) 2024-01-23
JP2026041823A (ja) 2026-03-10
CN120661512A (zh) 2025-09-19
CA3052873A1 (en) 2018-09-13
TW202517269A (zh) 2025-05-01
EP4487908A3 (en) 2025-01-15
AU2018230500A1 (en) 2019-09-19
US20220233527A1 (en) 2022-07-28
AU2018230500B2 (en) 2024-03-07
BR112019018576A2 (pt) 2020-04-14
JP2020510016A (ja) 2020-04-02
MX2022015499A (es) 2023-01-24
AU2024203642A1 (en) 2024-06-20
MX2019010733A (es) 2019-11-01
EP4487908A2 (en) 2025-01-08
US20190046527A1 (en) 2019-02-14
US11607411B2 (en) 2023-03-21
TWI851536B (zh) 2024-08-11
TW201840318A (zh) 2018-11-16
WO2018165581A1 (en) 2018-09-13
AU2024203642B2 (en) 2025-08-21
WO2022178492A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
AU2024203642B2 (en) Methods of treating Crohn's disease and ulcerative colitis
US10017517B2 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluorethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11564922B2 (en) Methods of treating crohn's disease and ulcerative colitis
TWI730935B (zh) Ｊａｋ１抑制劑之持續釋放劑型
CA3052873C (en) Use of upadacitinib to treat crohn's disease and ulcerative colitis
HK40123037A (en) Methods of treating crohn's disease and ulcerative colitis
HK40126875A (zh) 奥比塞曲匹与依折麦布组合治疗和固定剂量药物组合物
BR122022024891B1 (pt) Composição farmacêutica oral de liberação prolongada uma vez ao dia compreendendo (3s,4r)-3-etil-4-(3h-imidazo[1,2-a]pirrolo[2,3-e]pirazin-8-il)-n- (2,2,2-trifluoroetil)pirroli-dina-1-carboxamida
BR112018007677B1 (pt) Hemi-hidrato cristalino do composto (3s,4r)-3-etil-4-(3h-imidazo[1,2-a] pirrolo[2,3-e]pirazin-8-il)-n-(2,2,2-trifluoroetil)pirroli-dina-1-carboxamida
BR122022024907B1 (pt) Anidrato cristalino do composto (3s,4r)-3-etil-4-(3h-imidazo[1,2-a] pirrolo[2,3-e]pirazin-8-il)-n-(2,2,2-trifluoroetil)pirrolidina-1-carboxamida
BR122022024934B1 (pt) Base livre amorfa do composto (3s,4r)-3-etil-4-(3h-imidazo[1,2- a]pirrolo [2,3-e]-pirazin-8-il)-n-(2,2,2-trifluoroetil)pirrolidina-1- carboxamida e composição farmacêutica contendo a mesma
BR122022024919B1 (pt) Hidrato de tartarato cristalino do composto (3s,4r)-3-etil4-(3h-imidazo [1,2-a]pirrolo[2,3-e]pirazin-8-il)-n-(2,2,2-trifluoroetil)pirroli-dina-1-carboxamida
HK1263380B (en) PROCESS FOR THE PREPARATION OF IMIDAZO[1,2-α]PYRROLO[2,3-E]PYRAZINE COMPOUND

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination